S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
The single greatest medical breakthrough of all time? (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:OMCL

Omnicell (OMCL) Stock Forecast, Price & News

$72.24
-1.28 (-1.74%)
(As of 06/9/2023 ET)
Compare
Today's Range
$72.16
$74.09
50-Day Range
$57.88
$75.94
52-Week Range
$46.11
$125.17
Volume
211,803 shs
Average Volume
371,405 shs
Market Capitalization
$3.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.22

Omnicell MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
0.0% Downside
$72.22 Price Target
Short Interest
Bearish
6.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of Omnicell in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
107.69%
From $0.52 to $1.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.31 out of 5 stars

Medical Sector

947th out of 987 stocks

Health Information Services Industry

2nd out of 2 stocks


OMCL stock logo

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Omnicell (NASDAQ: OMCL)
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Omnicell (NASDAQ:OMCL) PT Raised to $70.00 at KeyCorp
Q1 2023 Omnicell Inc Earnings Call
Omnicell Announces First Quarter 2023 Results
Omnicell (OMCL) to Release Quarterly Earnings on Tuesday
Omnicell (OMCL) Gets a Buy from Bank of America Securities
See More Headlines

OMCL Price History

OMCL Company Calendar

Last Earnings
11/02/2021
Today
6/10/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Health Information Services
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
3,830
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$72.22
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
0.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$5.65 million
Pretax Margin
-2.26%

Debt

Sales & Book Value

Annual Sales
$1.30 billion
Cash Flow
$4.12 per share
Book Value
$25.52 per share

Miscellaneous

Free Float
43,837,000
Market Cap
$3.26 billion
Optionable
Optionable
Beta
0.89

Social Links


Key Executives

  • Mr. Randall A. LippsMr. Randall A. Lipps (Age 66)
    Founder, Exec. Chairman, Pres & CEO
    Comp: $1.2M
  • Mr. Corey J. Manley
    Exec. VP and Chief Legal & Admin. Officer
  • Mr. Peter J. KuipersMr. Peter J. Kuipers (Age 51)
    Exec. Adviser
    Comp: $694.07k
  • Mr. Nchacha Etta (Age 52)
    Exec. VP & CFO
  • Ms. Minoo Mortazavi
    Sr. VP of Global Operations
  • Mr. Joseph Brian SpearsMr. Joseph Brian Spears (Age 63)
    Sr. VP, Chief Accounting Officer & Corp. Controller
  • Mr. Virad Gupta
    Sr. VP & CTO
  • Mr. Giri Chodavarapu
    Sr. VP & Chief Information Officer
  • Ms. Kathleen Nemeth
    Sr. VP of Investor Relations
  • Mr. Maximo Rocha
    Sr. VP & Chief People Officer













OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price forecast for 2023?

8 Wall Street analysts have issued 1 year target prices for Omnicell's shares. Their OMCL share price forecasts range from $54.00 to $120.00. On average, they anticipate the company's share price to reach $72.22 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2023?

Omnicell's stock was trading at $50.42 at the beginning of 2023. Since then, OMCL shares have increased by 43.3% and is now trading at $72.24.
View the best growth stocks for 2023 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our OMCL earnings forecast
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Tuesday, November, 2nd. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.45. The company had revenue of $296.40 million for the quarter, compared to the consensus estimate of $283.82 million. Omnicell had a negative net margin of 1.39% and a positive trailing twelve-month return on equity of 5.38%. During the same period in the prior year, the company posted $0.40 earnings per share.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of $1.55-$1.80 for the period, compared to the consensus earnings per share estimate of $1.63. The company issued revenue guidance of $1.15 billion-$1.19 billion, compared to the consensus revenue estimate of $1.17 billion.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.46%), Clearbridge Investments LLC (2.65%), Conestoga Capital Advisors LLC (2.51%), ArrowMark Colorado Holdings LLC (2.23%), Champlain Investment Partners LLC (2.18%) and Geode Capital Management LLC (1.95%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $72.24.

How much money does Omnicell make?

Omnicell (NASDAQ:OMCL) has a market capitalization of $3.26 billion and generates $1.30 billion in revenue each year. The company earns $5.65 million in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Omnicell have?

The company employs 3,830 workers across the globe.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Investment LLC, 340B Link Business, 340B Link LLC, 340B Solutions LLC, Aesynt, Ateb Inc., FDS Amplicare, FDS Amplicare Company, FDS Inc., FDS Insurance Agency Inc., Flavma Inc., InPharmics, MTS Medication Technologies Inc., MTS Medication Technologies Inc., MTS Packaging Systems Inc., MarkeTouch Media LLC, MarkeTouch Media LLC, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd, Omnicell B.V., Omnicell GmbH, Omnicell India Private Limited, Omnicell International LLC, Omnicell Limited, Omnicell Pty Ltd, Omnicell S.r.l., Omnicell SAS, ReCept Cityview LLC, ReCept F&M LLC, ReCept Group Inc., ReCept Healthcare Services L.P., ReCept Holdings Inc., ReCept LLC, ReCept One LLC, ReCept Pharmacy, ReCept Pharmacy L.P., RxInnovation Inc., and ateb Inc..
Read More
How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (877) 415-9990, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -